Lab study shows omicron-blocking antibodies persist four months after a Pfizer-BioNTech booster
Companies, agencies, institutions, etc
Pfizer-BioNTech
the University of Texas Medical Branch
Brigham and Women’s Hospital
the Pfizer-BioNTech
La Jolla Institute
Immunology
Pfizer and
CDC
PCR
the White House
N95
Post
People
Pei-Yong Shi
Duane R. Wesemann
Shane Crotty
Fauci
Mask
N95s
Groups
German
Americans
Physical locations
No matching tags
Places
No matching tags
Locations
Galveston
erosion.“You
Boston
California
Britain
Israel
U.S.
Pfizer
Events
No matching tags
Summary
But researchers announced at a recent news conference that while a fourth shot sends antibodies higher, it does not appear to provide greater protection against symptomatic infection.Pfizer and BioNTech said in a statement Monday that they will soon be testing both a fourth dose of the original vaccine and an omicron-specific booster shot in human trials.The companies plan to manufacture 4 billion doses of their vaccine this year, regardless of whether they continue to make the original shot or revise it to battle the omicron variant, they said.Antibodies are just one easily measurable component of the immune response, and protection against severe illness and hospitalization can remain intact even as the level of antibodies drops off.The latest: According to the CDC, covid booster shots have strongly protected against severe disease from the omicron variant.
As said here by Carolyn Y. Johnson